We would like to respond to the insightful review by Andres and Clements that provides a detailed guide for the use of concentrated insulin, U-500 human regular insulin (U-500R), for pharmacists. 1 Andres and Clements describe U-500R as being 5 times more potent than U-100 human regular insulin (U-100R). 1 In the updated package insert (March 2013), U-500R is described as 5 times more concentrated than U-100R. 2 This means that there are 500 units in 1 mL of U-500R and 100 units in 1 mL of U-100R. There is no difference in units between both types of insulin. Accordingly, ''a unit is a unit'' meaning an equipotent unit of U-500R is delivered in one-fifth the volume than those of U-100 insulins. This has been frequently misstated even in expert commentaries 3, 4 and is crucial for pharmacists and prescribers to understand. To be completely unambiguous, the prescribed dose of U-500R should always be expressed in the actual units of insulin and the syringe markings to be administered in accordance with the syringe type to be used. 3, [5] [6] [7] Specifically, when the patient uses a U-100 insulin syringe, he or she should be educated on how to draw up the appropriate number of ''unit markings'' on the syringe corresponding to the desired actual dose (ie, unit markings equal to onefifth the actual units). Similarly, when the patient uses a volumetric (tuberculin or allergy) syringe, he or she should be educated on drawing up the appropriate volume (mL) of U-500R to be administered (ie, volume markings in mL equal to 1/500th the actual units). The current package insert (2013) has a conversion table for both unit markings (U-100 syringe) and volume (tuberculin or allergy syringe) to assist in accurate dosing. 2 Shortly after this information was added to the product label in 2011, the Institute for Safe Medication Practices published a summary of the label update, acknowledging that either syringe option could be used to administer U-500R. 8 Critically, the patient should know his or her prescribed dose in actual units of U-500R, which syringe to use, and how to draw up the prescribed dose, which will allow the patient to communicate his or her U-500R dose accurately to a new health care provider in emergency department or hospital settings. For outpatient administration of U-500R, the use of U-100 insulin syringes has become the standard and most common practice. 5, 6 The U-500R vial (20 mL containing 10 000 units of insulin) has distinctive brown diagonal stripes, black lettering on white background with additional red lettering with warnings on the label, and a gray flip-top to distinguish it from U-100 vials (10 mL containing 1000 units of insulin or 3 mL containing 300 units). 5, 6 The authors of the review state that U-100R and U-500R have similar pharmacokinetic (PK) profiles and that the PK profile of U-500R is similar to that of an intermediateacting insulin such as neutral protamine Hagedorn (NPH) insulin. 1 A euglycemic-clamp study by de la Peña et al describes a unique PK/pharmacodynamics (PD) profile for U-500R with prandial and basal activity while still showing similar overall insulin exposure (PK: area under the curve) and overall effect (PD: total glucose infused) to U-100R. 9 Both formulations demonstrate expected dose-dependent PK/ PD characteristics. However, U-500R has a prolonged time to the maximal effect (6.4 hours vs 5.3 hours) and longer duration of activity (21.5 hours vs 18.3 hours) after a 100-unit injection versus U-100R. 9 There are no data to suggest that U-500R is better absorbed than the U-100 formulation, and the extended duration of action of U-500R supports its use by multiple daily injections without concomitant use of U-100 insulins. [5] [6] [7] 9 There are special challenges with the use of U-500R in the hospital setting as noted in the Andres and Clements review. 1 Samaan et al provide a template for U-500R hospital formulary policy with critical safety precautions and procedures to implement when prescribing U-500R in a hospital setting. 10 This guidance includes a safety timeout with the pharmacist, the charge nurse, and the bedside nurse to perform a review of U-500R, the physician's order, and the medication administration record. 10 Deal and Tobin reported the beneficial impact of such a formulary policy in reducing hospital prescribing mistakes and hypoglycemia, 11 and other published expert clinical reviews have commented on hospital use of U-500R. [5] [6] [7] Andres and Clements provide a very useful case study 1 ; however, we would like to correct content from the case study because some of the conversions from U-100R to U-500R described in the review have errors in calculation. A division of total daily dose (TDD) by 5 on the basis of ''potency'' before syringe-specific conversion is unnecessary and inaccurate (see italicized text subsequently). The numbers used have been slightly modified (TDD 300 units substituted for 290 units as shown in the example) to result in syringe markings that can be measured on the respective syringe options (ie, increments of 1 ''unit marking'' or 0.01 mL correspond to 5 units of U-500R) and noting the prescribing advice of taking the dose 30 minutes before the meal. 2 These corrections reflect the fact that the difference between U-500 and U-100 concentrations is a difference in volume not units. The case study corrected calculations are given subsequently:
Case Study . . . To convert from U-100 insulin to U-500R, divide the TDD by 5 to determine the dose in unit markings when using a U-100 insulin syringe, and when using a volumetric syringe, divide the TDD by 500 to determine the dose in mLs.
To administer U-500R twice daily with 60% at breakfast and 40% in the evening as suggested by the review, the correct conversions are:
With a U-100 insulin syringe: Inject 120 units (24 unit markings on a U 100 syringe or 0.24 mL on a volumetric syringe) in the evening 30 minutes before the evening meal;
Patient Instructions for U-100 insulin syringe:
Draw to 36 unit markings 30 minutes before breakfast and 24 unit markings 30 minutes before the evening meal.
Patients instructions for volumetric syringe:
Draw to 0.36 mL 30 minutes before breakfast and 0.24 mL 30 minutes before the evening meal. In summary, the article by Andres and Clements provides an important guide for the use of U 500R for a crucially important audience: outpatient and hospital pharmacists. In conjunction with the review, we hope the additional resources and citations and the corrected Case Study in this letter will provide greater clarity to pharmacists and other health care providers in approaching and managing U 500R-treated patients in their clinical practices.
